EUVIMEDEUVIMED entdecken
Open Access

Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery

Jin Shentu iD, Mingjie Zhang iD, Zhuoming Xu iD, Chen Wen iD, Hao Zhang, Zhongqun Zhu, Huiwen Chen iD, Guocheng Shi iD

Journal of the American Heart Association · 18.02.2025 · 14 (4)

DOI: 10.1161/jaha.124.036911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 18.02.2025. Verfasst von Jin Shentu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-thoracic Surgery, Congenital Heart Center, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University …. Hauptthemen laut MEDLINE: Valsartan, Pulmonary Veins, Stenosis, Pulmonary Vein, Postoperative Complications. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recurrent pulmonary vein stenosis (PVS) following surgical repair of total anomalous pulmonary venous connection is associated with poor prognosis. Preclinical studies have shown that use of an angiotensin receptor blocker can attenuate intimal hyperplasia; notwithstanding, its clinical utility is of uncertain benefit.

Methods

This single‐center study included patients undergoing total anomalous pulmonary venous connection repair in 2020 to 2021. Since August 2020, patients have been considered for valsartan therapy early after operation. Contemporaneous participants were subcategorized into study versus control groups based on valsartan exposure. Patients in the control group were treated with the same protocolized algorithm except valsartan administration. The primary end point was postoperative PVS (PPVS) progression.

Results

Overall, 104 patients operated on at a median age of 1.3 months were included (valsartan group: 25 versus control group: 79). The baseline characteristics were similar between the 2 groups. Within a median follow‐up of 28.6 months, 27 patients developed PPVS noted by echocardiography and computed tomography angiography, among which 22 with clinical PPVS underwent reoperations. No between‐group difference was observed in the incidence of initial PPVS ( P =0.80, Cohen's h=0.06 [95% CI, −0.38 to 0.50]) and reoperation ( P =0.46, Cohen's h=−0.18[ 95% CI, −0.65 to 0.29]); however, patients in the valsartan group had a significantly lower risk of PPVS progression ( P =0.019, Cohen's h=−1.12 [95% CI, −1.66 to −0.57]) and subsequent PPVS progression after reoperation ( P =0.011, Cohen's h=−1.71 [95% CI, −2.61 to −0.82]) compared with the control group. PPVS‐related death was observed in 9 cases (11.4%) in the control group versus none (0%) in the valsartan group. No adverse event related to valsartan occurred in this series.

Conclusions

Early use of valsartan after total anomalous pulmonary venous connection surgery appears to potentially be a feasible and effective adjunct to reoperation in treating pediatric acquired PVS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanPulmonary VeinsStenosis, Pulmonary VeinPostoperative ComplicationsCardiac Surgical ProceduresHumansFemaleMaleInfantRetrospective StudiesTreatment OutcomeAngiotensin II Type 1 Receptor BlockersRecurrence

Stichwörter der Autor:innen

pulmonary vein stenosistotal anomalous pulmonary venous connectiontransforming growth factor‐βvalsartan

Substanzen

ValsartanAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Cardio-thoracic Surgery, Congenital Heart Center, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University Shanghai China.
  • Clinical Research Center, Shanghai Children's Medical Center, School of Medicine Shanghai Jiao Tong University Shanghai China.
  • Guizhou Branch of Shanghai Children's Medical Center Shanghai Jiaotong University School of Medicine Shanghai China.

ORCID-Profile: Jin Shentu, Mingjie Zhang, Zhuoming Xu, Chen Wen, Huiwen Chen, Guocheng Shi

Zitieren

APA

Shentu, J., Zhang, M., Xu, Z., Wen, C., Zhang, H., Zhu, Z., Chen, H., & Shi, G. (2025). Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery. Journal of the American Heart Association, 14(4). https://doi.org/10.1161/jaha.124.036911

Vancouver

Shentu J, Zhang M, Xu Z, Wen C, Zhang H, Zhu Z, et al. Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery. Journal of the American Heart Association. 2025;14(4). doi:10.1161/jaha.124.036911

BibTeX
@article{Shentu2025,
  author = {Shentu, Jin and Zhang, Mingjie and Xu, Zhuoming and Wen, Chen and Zhang, Hao and Zhu, Zhongqun and Chen, Huiwen and Shi, Guocheng},
  title = {Valsartan to Prevent Acquired Pulmonary Vein Stenosis in Pediatric Patients After Total Anomalous Pulmonary Venous Connection Surgery},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {4},
  doi = {10.1161/jaha.124.036911}
}
Kostenlos starten →